388 related articles for article (PubMed ID: 18096160)
21. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.
Bobrowska A; Paganetti P; Matthias P; Bates GP
PLoS One; 2011; 6(6):e20696. PubMed ID: 21677773
[TBL] [Abstract][Full Text] [Related]
22. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
23. Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity.
Anglada-Huguet M; Vidal-Sancho L; Giralt A; García-Díaz Barriga G; Xifró X; Alberch J
Neurobiol Dis; 2016 Nov; 95():22-34. PubMed ID: 26369879
[TBL] [Abstract][Full Text] [Related]
24. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
25. Laquinimod treatment in the R6/2 mouse model.
Ellrichmann G; Blusch A; Fatoba O; Brunner J; Reick C; Hayardeny L; Hayden M; Sehr D; Winklhofer KF; Saft C; Gold R
Sci Rep; 2017 Jul; 7(1):4947. PubMed ID: 28694434
[TBL] [Abstract][Full Text] [Related]
26. Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression.
Renoir T; Zajac MS; Du X; Pang TY; Leang L; Chevarin C; Lanfumey L; Hannan AJ
PLoS One; 2011; 6(7):e22133. PubMed ID: 21760962
[TBL] [Abstract][Full Text] [Related]
27. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
Hickey MA; Reynolds GP; Morton AJ
J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
[TBL] [Abstract][Full Text] [Related]
28. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease.
DeMarch Z; Giampà C; Patassini S; Bernardi G; Fusco FR
Neurobiol Dis; 2008 Jun; 30(3):375-387. PubMed ID: 18424161
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
[TBL] [Abstract][Full Text] [Related]
31. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
32. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
Pineda JR; Canals JM; Bosch M; Adell A; Mengod G; Artigas F; Ernfors P; Alberch J
J Neurochem; 2005 Jun; 93(5):1057-68. PubMed ID: 15934928
[TBL] [Abstract][Full Text] [Related]
33. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
[TBL] [Abstract][Full Text] [Related]
34. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
Gill JS; Jamwal S; Kumar P; Deshmukh R
Pharmacol Rep; 2017 Apr; 69(2):306-313. PubMed ID: 28178592
[TBL] [Abstract][Full Text] [Related]
35. Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis.
Fink KD; Rossignol J; Crane AT; Davis KK; Bombard MC; Bavar AM; Clerc S; Lowrance SA; Song C; Lescaudron L; Dunbar GL
Stem Cell Res Ther; 2013 Oct; 4(5):130. PubMed ID: 24456799
[TBL] [Abstract][Full Text] [Related]
36. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
[TBL] [Abstract][Full Text] [Related]
37. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
Harada A; Suzuki K; Kimura H
J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
[TBL] [Abstract][Full Text] [Related]
39. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
[TBL] [Abstract][Full Text] [Related]
40. The absence of the aryl hydrocarbon receptor in the R6/1 transgenic mouse model of Huntington's disease improves the neurological phenotype.
Angeles-López QD; García-Lara L; Aguirre-Pineda N; Castañeda-Arellano R; Elizondo-Azuela G; Pérez-Severiano F; Segovia J
Behav Brain Res; 2021 Jun; 408():113230. PubMed ID: 33684424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
